Glenmark
A new way for a new world

**November 6, 2012**

**The Manager**
**Listing Dept,**
**The National Stock Exchange of India Ltd**
**Plot No. C/1,G Block**
**Bandra Kurla Complex**
**Bandra (E) Mumbai-400051**

Dear Sir,

We are enclosing herewith a press release informing "**Glenmark Generics announces the settlement of Paragraph IV litigation with Janssen Pharmaceuticals, Inc.**"" for your information and record.

Thanking you,

Yours faithfully,
**For Glenmark Pharmaceuticals Ltd.**

**Marshall Mendonza**
**Vice President & Company Secretary**

Tel: 4018 9999 / 4018 9879
Fax No: 4018 9986 (Legal & Secretarial Dept.)

**Encl: As above**

Press Release For Immediate Release

**Glenmark Generics announces the settlement of Paragraph IV litigation with Janssen Pharmaceuticals, Inc.**

**Under the terms of the agreement, Glenmark will launch a generic version of ORTHO TRI-CYCLEN® LO tablets as early as December 31, 2015**

**Mumbai, India - 6 November, 2012:** Glenmark Generics Inc., USA (GGI), the United States subsidiary of Glenmark Generics Limited (GGL), today announced the settlement of litigation pending between Glenmark and Janssen Pharmaceuticals, Inc. (Janssen) over patent actions concerning Norgestimate and Ethinyl Estradiol Tablets USP, 0.18/0.025 mg, 0.215/ 0.025 mg and 0.25/0.025 mg tablets, the generic version of Janssen ORTHO TRI-CYCLEN® LO tablets.

Under the terms of the Settlement Agreements, Glenmark will be able to market and distribute its Norgestimate and Ethinyl Estradiol Tablets USP, 0.18/0.025 mg, 0.215/ 0.025 mg and 0.25/0.025 mg tablets under a royalty bearing license from Janssen on December 31, 2015, or earlier under certain circumstances.

Janssen currently markets its product as ORTHO TRI-CYCLEN® LO in the United States, indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Total U.S. sales as reported by IMS Health for the 12 month period ending June 2012 were approximately USD 397 million.

**About Glenmark Generics Limited**

Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America and developing an EU presence It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 63 countries, including the US, various countries in the EU, South America and India.

**For further information, please contact:**
Jason D'Souza / Rajdeep Barooah
Glenmark, Mumbai, India Tel: [+91 22] 40189919/984
Email : connect@glenmark-generics.com